Streetbeat News

NTRB

Nutriband Inc.

Industry

Biotechnology

Nutriband Inc. develops a portfolio of transdermal pharmaceutical products. The company's lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy. It also develops other products, which include AVERSA buprenorphine and AVERSA methylphenidate; exenatide for type 2 diabetes; and follicle stimulating hormone for infertility. Nutriband Inc. has a license agreement with Rambam Med-Tech Ltd. for the development of the RAMBAM Closed System Transfer Devices. The company was incorporated in 2016 and is headquartered in Orlando, Florida.

Open

N/A

Mkt cap

N/A

Volume

N/A

High

N/A

P/E Ratio

N/A

52-wk high

N/A

Low

N/A

Div yield

N/A

52-wk low

N/A

Nutriband announced the clinical development and regulatory pathway for Aversa Fentanyl, an abuse-deterrent fentanyl transdermal patch. The NDA will rely on a single Phase 1 human abuse potential clinical study, bypassing the need for Phase 2 or 3 trials. Aversa Fentanyl combines Nutriband's Aversa technology with an FDA-approved fentanyl patch, developed through a 505(b)(2) NDA pathway.

Portfolio Pulse from Benzinga Newsdesk

March 27, 2024 | 9:57 am

In Friday's after-market session, several healthcare stocks showed significant movement. Salarius Pharmaceuticals, Masimo, and Vicarious Surgical were among the top gainers, with Salarius Pharmaceuticals leading with a 33.9% increase. On the downside, NextCure, Rockwell Medical, and Mesoblast experienced declines, with NextCure dropping 9.5% following its Q4 earnings report. These movements reflect the dynamic nature of the healthcare stock market.

Portfolio Pulse from Benzinga Insights

March 22, 2024 | 9:33 pm

In Friday's pre-market session, several healthcare stocks showed significant movement. BIOL, OTLK, ETON, MGRM, OTRK, and NTRB were among the gainers, with BIOL leading by surging 61.5% after its Q4 earnings release. On the downside, SINT, CUTR, TBIO, GRFS, YTEN, and NKTX experienced declines, with SINT dropping 34%. CUTR and NKTX also released their Q4 earnings, impacting their stock prices.

Portfolio Pulse from Benzinga Insights

March 22, 2024 | 1:06 pm

Nutriband Inc. has signed a commercial development and clinical supply agreement with Kindeva Drug Delivery for Aversa Fentanyl, an abuse-deterrent fentanyl patch. This agreement will enable Kindeva to develop the manufacturing process and produce clinical supplies for FDA-required studies. Aversa Fentanyl, which combines Nutriband's proprietary technology with Kindeva's FDA-approved patch system, has a potential market of $80M - $200M in annual US sales. The technology aims to improve safety while ensuring access for patients in need.

Portfolio Pulse from Benzinga Newsdesk

January 05, 2024 | 2:21 pm

Nutriband Inc. has expanded its product line with the launch of AI Tape Heating and Cooling, which are additions to its AI Kinesiology Tape portfolio. These new products aim to provide users with the benefits of both heating and cooling therapy in conjunction with kinesiology taping techniques.

Portfolio Pulse from Benzinga Newsdesk

November 28, 2023 | 12:05 pm

Nutriband Inc. has signed a supplier agreement with Kinesiology Tape Company KT Tape. The details of the agreement were not disclosed.

Portfolio Pulse from Benzinga Newsdesk

November 08, 2023 | 12:24 pm

Nutriband Inc. has signed a supplier agreement with KT Tape. Nutriband's subsidiary, Active Intelligence, will act as the manufacturer for a new line of specialized KT Tape.

Portfolio Pulse from Benzinga Newsdesk

November 08, 2023 | 12:05 pm

Nutriband has completed the market assessment and commercialization strategy for Aversa Buprenorphine, an abuse-deterrent Buprenorphine transdermal system. The peak annual US sales for Aversa Buprenorphine is expected to reach $70M-130M.

Portfolio Pulse from Benzinga Newsdesk

October 11, 2023 | 11:46 am

Nutriband has announced a US patent for its AVERSA abuse-deterrent technology. The technology uses taste aversion to prevent the abuse of opioid-based transdermal patches.

Portfolio Pulse from Benzinga Newsdesk

September 20, 2023 | 11:36 am

Nutriband (NASDAQ:NTRB) reported Q2 losses of $(0.11) per share, an 8.33% improvement from $(0.12) per share YoY. Sales for the quarter were $655.93K, a 43.80% increase from $456.15K YoY.

Portfolio Pulse from Benzinga Newsdesk

September 11, 2023 | 11:07 am

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.